SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-070652
Filing Date
2023-03-15
Accepted
2023-03-15 07:10:59
Documents
13
Period of Report
2023-03-15
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d452341d8k.htm   iXBRL 8-K 27412
2 EX-99.1 d452341dex991.htm EX-99.1 18818
  Complete submission text file 0001193125-23-070652.txt   175618

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA stok-20230315.xsd EX-101.SCH 2880
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE stok-20230315_lab.xml EX-101.LAB 17978
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE stok-20230315_pre.xml EX-101.PRE 11278
7 EXTRACTED XBRL INSTANCE DOCUMENT d452341d8k_htm.xml XML 3341
Mailing Address 45 WIGGINS AVENUE BEDFORD MA 01730
Business Address 45 WIGGINS AVENUE BEDFORD MA 01730 781-430-8200
Stoke Therapeutics, Inc. (Filer) CIK: 0001623526 (see all company filings)

IRS No.: 471144582 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38938 | Film No.: 23733257
SIC: 2834 Pharmaceutical Preparations